Antibody drugs, characterized by high target specificity and well-defined mechanisms of action, have become one of the most important therapeutic modalities in the treatment of cancer, autoimmune diseases, and other major conditions. Driven by growing clinical demand, deepening technological innovation, and rapid product evolution, the global antibody drug market continues to expand steadily. Emerging modalities such as antibody-drug conjugates (ADCs) and bispecific antibodies are accelerating in development and are becoming key drivers of industry growth. Meanwhile, China’s antibody sector is strengthening its overall competitiveness under multiple tailwinds—including supportive policies, maturing technology platforms, enhanced industrial capabilities, and accelerating globalization—enabling it to integrate more deeply into the global biopharmaceutical innovation ecosystem and play an increasingly influential role in the global market.
Against this backdrop, Frost & Sullivan has prepared the Global Antibody Drug Industry Development Blue Book 2026, which provides a systematic overview of the current landscape and future trends of the global and China antibody industries, with in-depth analysis of market size and structural shifts, technological evolution, industrial chain development, and emerging areas. It aims to serve as a valuable reference for industry participants, investors, and researchers in assessing trends and making informed decisions.
